Continuation of psychostimulant medication during pregnancy in patients with ADHD does not increase risk of postpartum mental health admissions or new mood/anxiety disorders after adjusting for confounders.
Preexisting mental health diagnoses and medical comorbidities strongly predict adverse postpartum mental health outcomes, overshadowing psychostimulant use impacts.
This evidence alleviates concerns about psychostimulant discontinuation-associated postpartum mental health deteriorations in adherent pregnant people with ADHD.
